No Carolina / NY / Florida
Ph: 561.316.3330

Zeta Surgical Reports Mixed Reality Navigation System Receives FDA Special 510(k) Clearance for Expanded Functionality

Summation

  • “This new FDA clearance enables key enhancements in usability and performance, bringing us closer to achieving our mission of dramatically reducing the barriers to surgical navigation and unlocking its benefits for a wider array of patients and procedures.
  • Zeta Surgical, a surgical robotics and mixed reality company, announced today that its Zeta Cranial Navigation System has received Special 510(k) clearance from the U.
  • The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with “GPS-like”.

Zeta Surgical

Zeta Surgical, a surgical robotics and mixed reality company, announced today that its Zeta Cranial Navigation System has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded functionality through enhanced software features and compatibility with additional accessories.

Zeta Cranial Navigation System

The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with “GPS-like” guidance with millimetric accuracy in real-time. Zeta’s computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings. The platform received its first 510(k) clearance from the U.S. FDA in September 2023.

Dr. Roman Stolyarov, Chief Product Officer of Zeta Surgical, commented on the clearance:

“This new FDA clearance enables key enhancements in usability and performance, bringing us closer to achieving our mission of dramatically reducing the barriers to surgical navigation and unlocking its benefits for a wider array of patients and procedures.”

“We are thrilled to scale Zeta’s deployments in the U.S., building on its early successes in clinics,” said Jose Amich, Co-Founder and CEO of Zeta Surgical. “We look forward to seeing Zeta’s impact on patient outcomes and in the field of neuroscience.”

Other FDA News of Interest

XT-Thrive® Drug Master File (DMF) Accepted by the FDA | Reports X-Therma

X-Therma notes this DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines.

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.

Transforming Tricuspid Valve Care: FDA Gives Green Light to Abbott’s TriClip™

"The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy